Prostaglandins and cycloxygenases in the spinal cord
Introduction
Since it was proposed (Vane, 1971, Ferreira, 1972, Ferreira et al., 1973) that aspirin-like drugs cause analgesia by blocking the synthesis of prostaglandins (PGs), studies on PGs and on pain have fared hand in hand. Jurna (1997) has brought to our attention that in 1926 Hanzlick concluded that ‘the analgesic action of [the salicylates] is mainly central’ and that Woodbury, in the third edition (1965) of Goodman and Gilman's famous The Pharmacological Basis of Therapeutics, noted that ‘the salicylates are capable of alleviating certain types of pain by virtue of a selective depressant effect on the CNS’. And yet in the sixth edition of this textbook (1980) Flower, Moncada and Vane state that ‘aspirin works peripherally’ (Jurna, 1997), more in line with the findings of Lim et al. (1964). However, later experiments demonstrated that aspirin-like drugs, in addition to their peripheral action, indeed have antinociceptive effects by acting upon central nervous system (CNS) structures (Carlsson et al., 1986, Carlsson et al., 1988) including the spinal cord (Jurna et al., 1992, Malmberg and Yaksh, 1992a). Furthermore, the finding that both cyclooxygenase (COX) enzymes, i.e. COX-1 and COX-2 (see, e.g. Kaufmann et al., 1997, Vane et al., 1998), are expressed in the spinal cord has lent support to the idea that the non-steroidal anti-inflammatory drugs (NSAIDs) also act in the spinal cord by inhibiting PG synthesis.
The present review will thus deal with PGs, COXs and non-opioid analgesics from a neurobiological perspective as they involve the spinal cord and related structures. We shall first address the biochemical aspects of PG synthesis and COX molecules, as well as the location of COX-1 and COX-2 and the induction of their expression in the spinal cord. Then the PG types and their release, receptor types, and behavioral and cellular effects will be dealt with. Finally, the spinal effects of COX inhibitors will be reviewed.
Section snippets
Prostaglandins as products of cyclooxygenases
Arachidonic acid, the most abundant precursor of PGs in mammals, is cleaved from cell membrane phospholipids by the action of phospholipase A2 (PLA2) and phospholipase C (PLC) (Fig. 1A) (see Campbell and Halushka, 1996). These phospholipases are activated by a variety of intercellular and intracellular mediators (Axelrod et al., 1988). Arachidonic acid is in turn transformed into PGG2 and then PGH2 by the action of an enzyme variously called prostaglandin endoperoxide synthase, fatty acid
Basal expression and location of the cyclooxygenases
Both COX-1 and COX-2 mRNA and protein are constitutively expressed in brain and spinal cord, although the fact that synaptic activity induces COX-2 expression (Yamagata et al., 1993) may suggest that COX-2 is actually ‘constantly induced’ by neural activity (Section 3.3). These and other findings are presented in detail below. The degree to which expression in the various preparations is really ‘basal’ may of course be subject to discussion.
Prostaglandins in the spinal cord
Once arachidonic acid has given rise to PGH2 by the action of COX (Section 2.1), several enzymes come into play to synthesize the prostanoids. Thus hydroxyl and/or ketone groups are set on the cyclopentane ring to produce PGD2, PGE2 and PGF2α, and a new ring is formed upon the cyclopentane ring to form prostacyclin (PGI2) (Campbell and Halushka, 1996). Both arachidonic acid and the PGs can then subserve intracellular roles and can also be released into the extracellular space (Axelrod et al.,
Effects of spinal application of cyclooxygenase inhibitors
As mentioned in Sections 1 and 2, the most widely accepted explanation for the anti-inflammatory and analgesic effect of non-opioid analgesics is the inhibition of COX-mediated PG synthesis (Section 5.1), and this also how the NSAIDs are thought to act upon the spinal cord (Section 5.4.1). This explanation, however, leaves several questions unanswered and has thus been the subject of much discussion (cf. McCormack and Brune, 1991, Brune et al., 1993, McCormack, 1994, Geisslinger and Schaible,
Final comments
The story relating spinal COXs and PGs to spinal nociceptive mechanisms is neither complete nor homogeneous. This story is not made of several areas of knowledge whose borders have come to touch and fuse with one another; it is rather made of individual findings that mainly point in the same direction. Indeed, the induction of COX by conditions related to inflammation and pain, the increase in PG release caused by these conditions and by excitatory neuromediators, the enhancement by PGs of
Acknowledgements
Thanks are due for the bibliographic support received from the Thüringer Universitäts- und Landesbibliothek Jena, Zweigbibliothek Medizinisch-Theoretische Institute. The financial support received from the Deutsche Forschungsgemeinschaft, the Alexander-von-Humboldt-Stiftung and the Venezuelan CONICIT is also gratefully acknowledged.
References (178)
- et al.
Expression of tetrodotoxin-resistant sodium channels in capsaicin-sensitive dorsal root ganglion neurons of adult rats
Neurosci. Lett.
(1995) - et al.
Receptor-mediated activation of phospholipase A2 via GTP-binding proteins: arachidonic acid and its metabolites as second messengers
Trends Neurosci.
(1988) - et al.
Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs in the cerebrospinal fluid
Biomed. Pharmacother.
(1989) - et al.
Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
FEBS Lett.
(1996) - et al.
Localization of cycloogygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord
J. Neuroimmunol.
(1998) - et al.
Spinal and supraspinal antinociceptive action of dipyrone in formalin, capsaicin and glutamate tests. Study of the mechanism of action
Eur. J. Pharmacol.
(1998) - et al.
A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man
Pain
(1988) - et al.
Acetaminophen blocks spinal hyperalgesia induced by NMDA and substance P
Pain
(1994) - et al.
Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes
Eur. J. Pharmacol.
(1997) - et al.
Activation of inhibition from the periaqueductal grey matter mediates central analgesic effect of metamizol (dipyrone)
Pain
(1986)
Depression by morphine and the non-opioid analgesic agents metamizol (dipyrone), lysine acetylsalicylate, and paracetamol, of activity in rat thalamus neurones evoked by electrical stimulation of nociceptive afferents
Pain
The spinal and peripheral roles of bradykinin and prostaglandins in nociceptive processing in the rat
Eur. J. Pharmacol.
Noxious stimulus-induced increase in spinal prostaglandin E2 is noradrenergic terminal-dependent
Neurosci. Lett.
Cyclic AMP mediates the prostaglandin E2-induced potentiation of bradykinin excitation in rat sensory neurons
Neuroscience
Effect of spinal cyclooxygenase inhibitors in rat using the formalin test and in vitro prostaglandin E2 release
Eur. J. Pharmacol.
Activity-dependent neuronal plasticity following tissue injury and inflammation
Trends Neurosci.
The intraspinal release of prostaglandin E2 in a model of acute arthritis is accompanied by up-regulation of cyclo-oxygenase-2 in the spinal cord
Neuroscience
Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons
Brain Res.
Prostanoid synthesis in the spinal cord enhances excitability of dorsal horn convergent neurones during reperfusion of ischaemic receptive fields on the rat's tail
Pain
Co-expression of nociceptor properties in dorsal root ganglion neurons from the adult rat in vitro
Neuroscience
Role of a Ca2+-dependent slow after hyperpolarization in prostaglandin E2-induced sensitization of cultured rat sensory neurons
Neurosci. Lett.
COX-2 inhibitors
Lancet
Dexamethasone prevents the induction of COX-2 mRNA and prostaglandins in the lumbar spinal cord following intraplantar FCA in parallel with inhibition of oedema
Neuropharmacology
The potential role of spinal cord cyclooxygenase-2 in the development of Freund's complete adjuvant-induced changes in hyperalgesia and allodynia
Neuroscience
Prostacyclin enhances the evoked-release of substance P and calcitonin gene-related peptide from rat sensory neurons
Brain Res.
Intrathecal substance P-induced thermal hyperalgesia and spinal release of prostaglandin E2 and amino acids
Neuroscience
Dipyrone into the nucleus raphe magnus inhibits the rat nociceptive tail-flick reflex
Eur. J. Pharmacol.
Central effect of the non-steroid anti-inflammatory agents, indometacin, ibuprofen, and diclofenac, determined in C fibre- evoked activity in single neurones of the rat thalamus
Pain
Intrathecal injection of acetylsalicylic acid, salicylic acid and indomethacin depresses C fibre-evoked activity in the rat thalamus and spinal cord
Pain
Cyclooxygenases and the central nervous system
Prostaglandins
Expression of prostaglandin EP2 receptor mRNA in the rat spinal cord
Life Sci.
Antinociception produced by spinal delivery of the S and R enantiomers of flurbiprofen in the formalin test
Eur. J. Pharmacol.
Capsaicin-evoked prostaglandin E2 release in spinal cord slices: relative effect of cyclooxygenase inhibitors
Eur. J. Pharmacol.
Antinociceptive effect of spinally delivered prostaglandin E receptor antagonists in the formalin test on the rat
Neurosci. Lett.
Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions
Pain
Mapping of prostaglandin E2 binding sites in rat brain using quantitative autoradiography
Brain Res.
Prostacyclin receptor in the brain and central terminals of the primary sensory neurons: an autoradiographic study using a stable prostacyclin analogue ∣3H∣ iloprost
Neuroscience
Non-steroidal anti-inflammatory drugs and spinal nociceptive processing
Pain
Acute mechanical hyperalgesia in the rat can be produced by coactivation of spinal ionotropic AMPA and metabotropic glutamate receptors, activation of phospholipase A2 and generation of cyclooxygenase products
Prog. Brain Res.
The induction of pain: an integrative review
Prog. Neurobiol.
Allodynia evoked by intrathecal administration of prostaglandin F2α to conscious mice
Pain
Inhibition of prostaglandin synthesis in rat brain
Acta Pharmacol. Toxicol.
Effect of bradykinin and prostaglandins on the release of calcitonin gene-related peptide-like immunoreactivity from the spinal cord in vitro
Br. J. Pharmacol.
Some rat sensory neurons in culture express characteristics of differentiated pain sensory cells
Proc. Natl. Acad. Sci. USA
Central analgesic effects of aspirin-like drugs
Fundam. Clin. Pharmacol.
Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis
Inflamm. Res.
Prostaglandins stimulate calcium-dependent glutamate release in astrocytes
Nature (London)
Accumulation and apparent active transport of prostaglandins by some rabbit tissues in vitro
J. Physiol. (London)
Impermeability of rabbit erythrocytes to prostaglandins
Am. J. Physiol.
Central, naloxone-reversible antinociception by diclofenac in the rat
Naunyn-Schmiedeberg's Arch. Pharmacol.
Cited by (356)
Revisiting prostaglandin E2: A promising therapeutic target for osteoarthritis
2024, Clinical ImmunologyNeurokinin 1 and 2 receptors are involved in PGE<inf>2</inf>- and citric acid-induced cough and ventilatory responses
2022, Respiratory Physiology and NeurobiologyCitation Excerpt :In the present study, CA-exposure for 10 min enhances pulmonary SP and NKA contents by 3-fold and ~60% respectively, consistent with the previous report in which inhalation of CA for 15 min increases pulmonary SP by ~2-fold in pigs (Moreaux et al., 2000). Although previous studies showed that PGE2 stimulated C-fibers and PCFs (Bergren, 2006; Gao et al., 2021; Vanegas and Schaible, 2001), it was unclear if PGE2-exposure increased pulmonary SP and NKA. This study reveals that different from CA, PGE2-exposure increases pulmonary NKA (~60%), but not SP, contents.
On the therapeutic targets and pharmacological treatments for pain relief following spinal cord injury: A mechanistic review
2021, Biomedicine and Pharmacotherapy